In the world of Alzheimer's drug research, there's no lack of certainty among leading researchers. There's just no consensus on what causes the disease or how to treat it.
Up until now, most of the work focused on the amyloid beta theory on Alzheimer's has concentrated on drugs that can clear the toxic protein clusters many believe trigger brain damage and memory loss. But a team in Australia has been winning headlines around the world after demonstrating in mice that they can do the same thing with an ultrasound approach.
As scientists home in on innovative technology to treat neurodegenerative conditions such as Alzheimer's, a new study shows that ultrasound therapy could help reduce symptoms associated with the disease in mice.
Phase II results of the first clinical trial of a tau aggregation inhibitor for Alzheimer's disease were published last month in the Journal of Alzheimer's Disease, with Singapore-based TauRx Pharmaceuticals saying it was an important milestone as it moves to report top line results from a Phase III study in 2016.
Researchers have discovered that a skin sample taken from behind the ear of patients with either Alzheimer's or Parkinson's disease had levels of the protein tau 7 times higher than those without the condition. Those with Parkinson's showed levels of alpha-synuclein protein that were 8 times higher than those in the control group.
Akili Interactive Labs has partnered with the nonprofit Autism Speaks to conduct a clinical trial of its cognitive assessment and personalized treatment video game.
Scientists at some of the most prestigious research institutions in the U.K. and Sweden say they've found a molecule that could disarm the toxic clusters of amyloid beta that are believed to trigger Alzheimer's, offering a new approach to treating the disease.
Japan's Sosei Group said it has acquired all of Heptares Therapeutics, a U.K.-based biotech focused on Alzheimer's disease and diabetes.
Alzheimer's Research UK is setting up a trio of discovery units in the Golden Triangle with plans to recruit dozens of investigators to advance new work on therapeutics for the memory-robbing disease.
The former head of Johnson & Johnson's initiative to develop stratified drugs for Alzheimer's disease is trying to crowdfund the development of computer simulations of brain disorders. Magali Haas is seeking $299,900 for the project, which builds on a multiple sclerosis prediction model created by her nonprofit, Orion Bionetworks.